Patents by Inventor Sameh Hamdy Abdelmageed Soror

Sameh Hamdy Abdelmageed Soror has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazole-based compounds as hepatitis C virus inhibitors
    Patent number: 10959987
    Abstract: Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: March 30, 2021
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El-Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Hassan Bamane
  • COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN
    Publication number: 20200368204
    Abstract: Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 26, 2020
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El-Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Hassan Bamane
  • COMPOSITION AND METHOD FOR TREATING A PATIENT HAVING LIVER CIRRHOSIS
    Publication number: 20200369727
    Abstract: Peptide inhibitors of activation of hepatitis C virus (HCV) NS3 protease are disclosed. They are analogs of the activation peptide HCV NS4 of residues 21-33 of SEQ ID NO: 2 and contain non-proteinogenic amino acids. Competitive binding studies showed the peptide analogs bind HCV NS3 protease at the activation site.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 26, 2020
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El-Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Hassan Bamane
  • Compounds for inhibiting NS3 and compositions containing the inhibited protein
    Patent number: 10821096
    Abstract: Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: November 3, 2020
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El-Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Hassan Bamane
  • IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
    Publication number: 20200323822
    Abstract: Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.
    Type: Application
    Filed: April 15, 2019
    Publication date: October 15, 2020
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El-Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Bamane
  • PEPTIDE INHIBITORS OF HCV NS3/4A PROTEASE COMPRISING NON-PROTEINOGENIC AMINO RESIDUES
    Publication number: 20200308228
    Abstract: Peptide inhibitors of activation of hepatitis C virus (HCV) NS3 protease are disclosed. They are analogs of the activation peptide HCV NS4 of residues 21-33 of SEQ ID NO: 2 and contain non-proteinogenic amino acids. Competitive binding studies showed the peptide analogs bind HCV NS3 protease at the activation site.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 1, 2020
    Applicant: King Abdulaziz University
    Inventors: Moustafa E. EL-ARABY, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El- Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Hassan Bamane